CSPC Pharma Initiates Phase II Study of Small-Molecule RSV Inhibitor SYH2066 in China

Bulletin Express

Oct 22

CSPC Pharmaceutical Group Limited (CSPC Pharma) has commenced a multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial of its investigational RSV therapeutic SYH2066 tablets at the first site in China.

SYH2066 is a Class 1 small-molecule fusion (F) protein inhibitor designed to block the conformational change required for respiratory syncytial virus (RSV) to fuse with host-cell membranes, thereby preventing viral entry and replication.

Regulatory status and prior data: • The National Medical Products Administration granted a Notice of Approval for Clinical Trial of Drug for SYH2066 in September 2025. • A single-centre Phase I study evaluating single and multiple ascending doses in healthy Chinese participants confirmed a favourable safety and pharmacokinetic profile following oral administration.

Current Phase II objectives: • Assess efficacy and safety in adult patients with confirmed RSV infection. • Participant recruitment and screening are now underway across multiple clinical centres in China.

The Board highlighted that the trial launch marks a key development milestone for CSPC Pharma’s antiviral pipeline, advancing SYH2066 into patient-based efficacy evaluation following encouraging Phase I results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1184841765"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184841765\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184841765?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-22 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184841765","market":"us","top_or_hot":-1,"title":"CSPC Pharma Initiates Phase II Study of Small-Molecule RSV Inhibitor SYH2066 in China","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has commenced a multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial of its investigational RSV therapeutic SYH2066 tablets at the first site in China.</p>\n<p>SYH2066 is a Class 1 small-molecule fusion (F) protein inhibitor designed to block the conformational change required for respiratory syncytial virus (RSV) to fuse with host-cell membranes, thereby preventing viral entry and replication.</p>\n<p>Regulatory status and prior data:\n• The National Medical Products Administration granted a Notice of Approval for Clinical Trial of Drug for SYH2066 in September 2025.  \n• A single-centre Phase I study evaluating single and multiple ascending doses in healthy Chinese participants confirmed a favourable safety and pharmacokinetic profile following oral administration.</p>\n<p>Current Phase II objectives:\n• Assess efficacy and safety in adult patients with confirmed RSV infection.  \n• Participant recruitment and screening are now underway across multiple clinical centres in China.</p>\n<p>The Board highlighted that the trial launch marks a key development milestone for CSPC Pharma’s antiviral pipeline, advancing SYH2066 into patient-based efficacy evaluation following encouraging Phase I results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Initiates Phase II Study of Small-Molecule RSV Inhibitor SYH2066 in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Initiates Phase II Study of Small-Molecule RSV Inhibitor SYH2066 in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-10-22 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) has commenced a multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial of its investigational RSV therapeutic SYH2066 tablets at the first site in China.</p>\n<p>SYH2066 is a Class 1 small-molecule fusion (F) protein inhibitor designed to block the conformational change required for respiratory syncytial virus (RSV) to fuse with host-cell membranes, thereby preventing viral entry and replication.</p>\n<p>Regulatory status and prior data:\n• The National Medical Products Administration granted a Notice of Approval for Clinical Trial of Drug for SYH2066 in September 2025.  \n• A single-centre Phase I study evaluating single and multiple ascending doses in healthy Chinese participants confirmed a favourable safety and pharmacokinetic profile following oral administration.</p>\n<p>Current Phase II objectives:\n• Assess efficacy and safety in adult patients with confirmed RSV infection.  \n• Participant recruitment and screening are now underway across multiple clinical centres in China.</p>\n<p>The Board highlighted that the trial launch marks a key development milestone for CSPC Pharma’s antiviral pipeline, advancing SYH2066 into patient-based efficacy evaluation following encouraging Phase I results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1184841765","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184841765","pubTimestamp":1792666949,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has commenced a multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial of its investigational RSV therapeutic SYH2066...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团在中国启动小分子RSV抑制剂SYH2066 II期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) has commenced a multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial of its investigational RSV therapeutic SYH2066 tablets at the first site in China.\nSYH2066 is a Class 1 small-molecule fusion (F) protein inhibitor designed to block the conformational change required for respiratory syncytial virus (RSV) to fuse with host-cell membranes, thereby preventing viral entry and replication.\nRegulatory status and prior data:\n• The National Medical Products Administration granted a Notice of Approval for Clinical Trial of Drug for SYH2066 in September 2025.  \n• A single-centre Phase I study evaluating single and multiple ascending doses in healthy Chinese participants confirmed a favourable safety and pharmacokinetic profile following oral administration.\nCurrent Phase II objectives:\n• Assess efficacy and safety in adult patients with confirmed RSV infection.  \n• Participant recruitment and screening are now underway across multiple clinical centres in China.\nThe Board highlighted that the trial launch marks a key development milestone for CSPC Pharma’s antiviral pipeline, advancing SYH2066 into patient-based efficacy evaluation following encouraging Phase I results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}